# An Integrated Data Driven Approach to Drug Repositioning Using Gene-Disease Associations.

- **DOI:** [10.1371/journal.pone.0155811](https://doi.org/10.1371/journal.pone.0155811)
- **Rating:** Sound (3.2 out of 5)
- **Verdict:** A useful integrative drug-repositioning workflow that scales gene-disease mining, but remains limited by retrospective validation.
- **Framework version:** v5.0
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-07-02
- **Evaluation page:** https://www.nabu.science/paper/10.1371%2Fjournal.pone.0155811

## Strengths

- **Large-scale integrated repositioning resource** The paper integrates ranked gene-disease evidence with drug, target, protein, disease, indication, and side-effect data in a Neo4j network. It reports 55,973 nodes, 529,738 edges, and 275,934 inferred unique drug-disease associations after filtering.
  - Dimension: contribution
  - Location: Materials and Methods, Integrated Dataset; Results, Mining
- **Transparent pipeline counts and filtering** The mining workflow reports a clear sequence from 539,162 raw mappings through side-effect, directionality, and ADME filtering to 451,269 retained mappings. These counts make the computational pipeline unusually traceable for a hypothesis-generation study.
  - Dimension: methodological rigour
  - Location: Results, Mining
- **Candid discussion of false-positive mechanisms** The Discussion explains how missing directionality could make the top CNS inference, Nitrendipine for hypokalemic periodic paralysis, harmful rather than therapeutic. This example grounds the limitation in a concrete failure mode rather than a generic caveat.
  - Dimension: reporting
  - Location: Discussion, paragraph on directionality and Nitrendipine

## Limitations

- **Retrospective tuning weakens performance claims** The D parameter and MeSH similarity thresholds are selected because they optimise AUC or trade-offs on the available data. This makes the reported performance less convincing as evidence of prospective predictive ability.
  - Dimension: methodological rigour
  - Location: Results, Ranking Gene-Disease Associations; Results, Mining; Discussion, paragraph on Sim values
- **Validation is not clearly independent** Known has_indication associations used for validation are drawn from the same integrated network environment that supports prediction. The 72.65% recovery rate and AUC of 0.73 therefore mainly support retrospective recovery, not out-of-sample drug-repositioning performance.
  - Dimension: methodological rigour
  - Location: Materials and Methods, Integrated Dataset; Results, Mining; Fig 5
- **Application pathway remains underdeveloped** The article identifies a real drug-repositioning need and provides downloadable outputs, but it does not describe how industry or academic teams should use the ranked associations to select candidates for validation. Highlighted examples such as Pazopanib and Lisinopril remain literature-supported hypotheses rather than tested repositioning leads.
  - Dimension: application pathway
  - Location: Results, Pazopanib and Lisinopril sections; Discussion

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The workflow and reported counts are broadly internally coherent, but several performance-related choices are tuned on the available data and validation is not clearly out-of-sample. A redacted citation placeholder for the key subgraph algorithm also limits documentation of one methodological dependency without contradicting the numerical results.
- **Research conduct:** Noted. The study uses public computational resources and presents no ethics or fabrication concerns, but reproducibility claims depend on repository contents and supplementary mapping files that were not verified in the supplied material. Claimed data and Java code availability are specific enough to record, but not independently confirmed here.
- **Reference integrity:** Clean. All 58 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17